New drug combo aims to overcome resistance in lung cancer treatment

NCT ID NCT04895579

Completed Disease control Sponsor: Zhonglin Hao Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether adding copanlisib to the standard immune therapy durvalumab is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 11 participants who had already received chemotherapy and radiation. The main goal was to check for side effects and find the best dose, with a secondary look at how well the tumors responded.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Copanlisib (Aliqopa) and Durvalumab (Imfinzi)
What this could lead to: If this combination is safe and effective, it could offer a new option to improve outcomes for people with advanced lung cancer who are already on durvalumab.
What could go wrong: This is a very early phase 1 trial with only 11 participants, so results may not apply to everyone. The main goal is safety, not yet proof of benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Markey Cancer Center

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.